Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
CME Credit Available: Maximum of 6.0 AMA PRA Category 1 Credits™
Release Date: January 5, 2010
Expiration Date: January 5, 2011
This activity consists of audio and visual recording of 6 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view a presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. The learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Design antiretroviral strategies that consider current data on:
- When to initiate therapy
- Initial therapy regimens
- Managing treatment failure
- Describe the clinical and epidemilogical characteristics of HIV patients from the Caribbean
- Identify and apply new strategies for HIV testing
- Describe the state of the H1N1 influenza epidemic as it impacts HIV-infected individuals
- Formulate appropriate management strategies for the aging HIV-infected population
- Consider current data on new hepatitis C drugs as they impact HIV coinfection treatment
CME Credit
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of
6 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Douglas T. Dieterich, MD, FACP
Course Chair
Professor of Medicine
Mount Sinai School of Medicine
Department of Medicine
New York, New York
Roy M. Gulick, MD, MPH
Course Vice-Chair
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Professor of Medicine
Chief, Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Speakers
Judith A. Aberg, MD
Associate Professor of Medicine
New York University Medical Center
Division of Infectious Diseases and Immunology
Director of Virology
Director, AIDS Clinical Trials Unit
Bellevue Hospital Center
New York, New York
Eric S. Daar, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Torrance, California
Demetre C. Daskalakis, MD
Assistant Professor
New York University Medical Center
Division of Infectious Diseases
Bellevue Hospital Center
New York, New York
Mari M. Kitahata, MD, MPH
Associate Professor of Medicine
Director Clinical Epidemiology and
Health Services Research
Center for AIDS Research
University of Washington
Seattle, Washington
Anne Moscona, MD
Professor of Pediatrics and of Microbiology and
Immunology
Vice Chair of Pediatrics for Research
Chief, Pediatric Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Jean William Pape, MD
Professor of Medicine
Weill Medical College of Cornell University
Division of International Medicine and
Infectious Diseases
Director, Les Centres GHESKIO
New York, New York
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on advisory boards for GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc, and chaired data and safety monitoring boards for Johnson & Johnson Research, Ltd (Australia) and Achillion Pharmaceuticals, Inc. (Updated 02/12/09)
Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California, Los Angeles from Merck & Co, Inc, Schering-Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. She has served as a scientific advisor to Bristol-
Myers Squibb, Merck & Co, Inc, and has served on data and safety monitoring boards for Achillion Pharmaceuticals, Inc, and Koronis Pharmaceuticals. (Updated 10/09/09)
Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from the National Institutes of Health, the US Centers for Disease Control and Prevention, Merck & Co, Inc, and Sanofi Pasteur. He served as a consultant to, or received
honoraria from, Bristol-Myers Squibb, Merck & Co, Inc, and Janssen-Cilag. (Updated 10/02/09)
Joel E. Gallant, MD, MPH
Dr Gallant has served as a paid lecturer for Monogram Biosciences and has been a consultant to Abbott Laboratories, GlaxoSmithKline, Japan Tobacco, Merck Serono, and Pfizer, Inc. He has been a member of the data and safety monitoring boards for Koronis and VIRxSYS, served on an endpoint adjudication committee for Gilead Sciences, and been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Serono, Pfizer, Inc, and RAPID Pharmaceuticals AG. Dr Gallant has been the recipient of research grants or contracts from Roche Laboratories. (Updated 06/25/09)
Roy M. Gulick, MD, MPH
Dr Gulick has received research support from Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tibotec Therapeutics, and has served as an ad hoc consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Virostatics. He also serves as Chair of a data and safety monitoring board for Koronis Pharmaceuticals. (Updated 10/26/09)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 10/27/09)
Douglas D. Richman, MD
Dr Richman has been a consultant to Anadys Pharmaceuticals, Inc, Biota, Bristol-Myers Squibb, Chimerx, Gen-Probe, Inc, Gilead Sciences, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, Myriad Genetics, Inc, Pfizer Inc, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. He has been a stock options holder of Chimerx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated: 10/09/09)
Michael S. Saag, MD
Dr Saag has received grants and research support from Achillion Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, and Tibotec Therapeutics. He has served as a consultant to Ardea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, and Tobira Therapeutics. (Updated 10/01/09)
Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Chimerix, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, Koronis Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, TaiMed Biologics, Tibotec Therapeutics, and Vertex Pharmaceuticals. He had stock options for Achillion Pharmaceuticals, Inc, and Monogram Biosciences, Inc. (Updated 10/05/09)
Paul A. Volberding, MD
Dr Volberding has been a member of the data and safety monitoring boards Merck & Co, Inc and TaiMed Biologics and on an endpoint adjudication committee for Schering-Plough Corporation. He has provided paid legal consultation and expert testimony for commercial firms. Dr Volberding has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, Inc, and Tobira Therapeutics and he has been the recipient of service grants or contracts for GlaxoSmithKline Italy. (Updated 10/08/09)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Aberg has been a scientific advisor to Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. She participates in multicenter clinical trials funded by Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. Dr Aberg currently holds nonsalaried contracts for pending multicenter clinical trials with Adamas Pharmaceuticals, Inc, and Wyeth Pharmaceuticals. (Updated 10/06/09)
Dr Daar has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tibotec Therapeutics, or as a contracted researcher for Abbott Laboratories, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc. He has received honoraria for CME activities funded by Bristol-Myers Squibb, Merck & Co, Inc, and Tibotec Therapeutics. (Updated 10/09/09)
Dr Daskalakis has no relevant financial affiliations to disclose. (Updated 10/05/09)
Dr Dieterich has served as a consultant to or as a contracted researcher for Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead
Sciences, Inc, and Roche Pharmaceuticals. He has received honoraria from or has served on the speakers’ bureaus of Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, GileadSciences, Inc, and Roche Pharmaceuticals.
(Updated 09/16/09)
Dr Gulick has received research support from Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tibotec Therapeutics, and has served as an ad hoc consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Virostatics. He also serves as Chair of a data and safety monitoring board for Koronis Pharmaceuticals. (Updated 10/26/09)
Dr Kitahata has served as a consultant to Gilead Sciences, Inc. (Updated 08/26/09)
Dr Moscona has served as a consultant to or received honoraria from GlaxoSmithKline, MedImmune, and Merck & Co, Inc. She served as
a contracted researcher for NexBio and Shaklee Corporation or has been on the speakers’ bureaus of MedImmune and Merk & Co, Inc. (Updated 10/26/09)
Dr Pape has no relevant financial affiliations to disclose. (Updated 09/09/09)
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Merck & Co., Inc.
Gilead Sciences
Pfizer Inc
Generous Grant from:
GlaxoSmithKline
Additional grant support for this course provided by:
Roche Pharmaceuticals
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org
